Patient Resources

 

 
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Certolizumab Pegol In Combination With Methotrexate For Inducing And Sustaining Clinical Response In The Treatment Of Dmard-Naïve Adults With Early Active Rheumatoid Arthritis
Principal Investigator (?)
Study Number
F12081
Summary
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in
combination with Methotrexate (MTX) for inducing and sustaining clinical response in the
treatment of Disease Modifying Antirheumatic Drug (DMARD)-naïve adults with early active
Rheumatoid Arthritis.
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Lebanon

Contact

Cheryl Carlson
(603) 650-4717

View more details from ClinicalTrials.gov.